Spectrum Pharmaceuticals, Inc. announced the promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer (CCO). Mr. Turgeon joined Spectrum in October 2012 as Senior Vice President Sales & Commercial Operations, bringing over 25 years of pharma sales experience, including various executive leadership roles at Amgen. In his new capacity as CCO, Mr. Turgeon will be responsible for global commercial and sales activities, reporting to Spectrum Pharmaceuticals' Executive Vice President, Chief Operating Officer, Ken Keller.

Currently, Spectrum markets three oncology products in the U.S. FUSILEV(R) (levoleucovorin) for Injection; FOLOTYN(R) (pralatrexate injection); and ZEVALIN(R) (ibritumomab tiuxetan) Injection for intravenous use with ex-U.S. rights for ZEVALIN as well. The company also announced the further expansion of its sales and marketing leadership, with the appointments of Robert Fralin as Vice President of Sales and Al DeJesus as Executive Director, Marketing. Previously, Mr. Fralin served as Executive Director of Amgen's Bone Health Business Unit and prior to that, as Executive Director of Amgen's Oncology Business Unit, which had annual revenues exceeding $1 billion.

Mr. DeJesus is the former Executive Director of Amgen's Global Oncology Marketing, with responsibilities including worldwide planning for Amgen's oncology products and global partnerships. Both individuals will report directly to Mr. Turgeon.